Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

72.5K
Overview
72.5K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

933
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
933
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dengue virus nonstructural proteins as small-molecule targets: Advances, challenges, and future directions.

European journal of medicinal chemistry·2026
Same author

Saroglitazar, a novel PPAR-α/γ agonist, modulates thyroid hormone homeostasis through hepatic UGT expression in wistar rats.

Chemico-biological interactions·2026
Same author

Case Report: Post-stroke hemorrhagic infarction in a status epilepticus Beagle dog.

Frontiers in veterinary science·2026
Same author

Pair-Feeding Differentiates Feed-Dependent and Pharmacodynamic Effects of Telmisartan in Wistar Rats.

International journal of toxicology·2026
Same author

Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats.

The Journal of antimicrobial chemotherapy·2026
Same author

Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia.

Vaccines·2025

Related Experiment Video

Updated: Jun 21, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K

HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases.

Vishal J Patel1, Amit A Joharapurkar1, Samadhan G Kshirsagar1

  • 1Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Moraiya, Ahmedabad, India.

Drug Research
|July 11, 2024
PubMed
Summary

Desidustat, a hypoxia-inducible factor (HIF) stabilizer, reduces kidney and retinal damage in complement-mediated diseases by inhibiting the alternative complement system. This study highlights desidustat

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

11.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

281

Related Experiment Videos

Last Updated: Jun 21, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

11.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

281

Area of Science:

  • Immunology
  • Nephrology
  • Ophthalmology

Background:

  • The complement cascade is crucial for host defense but its dysregulation, particularly the alternative pathway, drives inflammatory kidney and retinal diseases.
  • Inflammation-induced tissue hypoxia activates hypoxia-inducible factor (HIF), a key regulator of cellular adaptation.
  • The therapeutic potential of targeting HIF in complement-mediated pathologies remains largely unexplored.

Purpose of the Study:

  • To investigate the efficacy of the HIF stabilizer desidustat in preclinical models of complement-mediated kidney and retinal diseases.
  • To elucidate the mechanism by which desidustat impacts complement activation and associated pathology.

Main Methods:

  • Desidustat (15 mg/kg) was orally administered to mice subjected to kidney injury models (LPS, doxorubicin, BSA-overload) and retinal degeneration models.
  • Complement activation markers (MAC formation, Factor B activity, C3 deposition) and disease-specific parameters (proteinuria, oxidative stress markers, inflammatory cytokines) were assessed.
  • The effect of desidustat on different complement pathways (alternative, lectin, classical) was evaluated.

Main Results:

  • Desidustat significantly ameliorated kidney injury across multiple models and reduced retinal degeneration.
  • Treatment with desidustat decreased complement activation, including membrane attack complex (MAC) formation and factor B activity.
  • In membranous nephropathy, desidustat reduced C3 deposition, proteinuria, malondialdehyde, and IL-1ß, while increasing superoxide dismutase, specifically by inhibiting the alternative complement pathway via Factor B.

Conclusions:

  • Desidustat effectively mitigates tissue damage in complement-mediated kidney and retinal diseases.
  • The therapeutic benefit of desidustat is attributed to its specific inhibition of the alternative complement pathway, mediated by Factor B.
  • HIF stabilization with desidustat presents a promising therapeutic strategy for managing complement-mediated inflammatory diseases.